Genetic variants in key necroptosis regulators predict prognosis of non‐small cell lung cancer after surgical resection

BACKGROUND Necroptosis is a regulated inflammatory cell death which plays a significant role in cancer development and progression. In this study, we evaluated whether genetic variants in key regulators of necroptosis may affect survival outcome of non-small cell lung cancer (NSCLC) patients after surgical resection. METHODS A total of 674 patients who underwent curative surgery were included. Fifteen genetic variants in key regulators of necroptosis (RIPK1, RIPK3, and MLKL) were selected. The association of these variants with survival outcomes was evaluated. RESULTS Two variants, RIPK1 rs17548629C > T and MLKL rs877375G > C, were associated with better overall survival and disease-free survival in multivariate analyses. When the patients were divided according to histology, the associations were significant only in adenocarcinoma, but not in squamous cell carcinoma. RIPK1 rs17548629 C-to-T change was associated with significantly increased luciferase activity by modulating the binding of miR-642a. Promoter assays showed a significantly increased promoter activity in MLKL rs877375C allele compared to G allele. Consistently, the mRNA expression level of RIPK1 and MLKL showed significant positive correlation with RIPK1 rs17548629C-to-T and MLKL rs877375G-to-C changes. CONCLUSION Two genetic variants in key regulators in necroptosis, RIPK1 rs17548629C > T and MLKL rs877375G > C, may be used as biomarkers to predict survival outcomes in surgically resected NSCLC patients.

[1]  M. Mori,et al.  Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study , 2022, JTCVS open.

[2]  A. Chella,et al.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.

[3]  D. Oh,et al.  Necroptosis molecular mechanisms: Recent findings regarding novel necroptosis regulators , 2021, Experimental & Molecular Medicine.

[4]  H. Stunnenberg,et al.  The Role of Necroptosis: Biological Relevance and Its Involvement in Cancer , 2021, Cancers.

[5]  Chuan-Qi Zhong,et al.  RIP1-dependent linear and nonlinear recruitments of caspase-8 and RIP3 respectively to necrosome specify distinct cell death outcomes , 2021, Protein & cell.

[6]  Hui Yu,et al.  Bioinformatics analysis of differentially expressed miRNAs in non‐small cell lung cancer , 2020, Journal of clinical laboratory analysis.

[7]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[8]  Susan M. Schlenner,et al.  Necroptosis in Immuno-Oncology and Cancer Immunotherapy , 2020, Cells.

[9]  E. Lee,et al.  Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer , 2020, Journal of Cancer.

[10]  L. Cai,et al.  Single-nucleotide polymorphism rs17548629 in RIPK1 gene may be associated with lung cancer in a young and middle-aged Han Chinese population , 2020, Cancer Cell International.

[11]  Zhangfeng Zhong,et al.  ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. , 2020, Cancer letters.

[12]  Jun Hee Han,et al.  Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection. , 2019, Annals of translational medicine.

[13]  Chao Yang,et al.  The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.

[14]  D. Sharma,et al.  Necroptosis: a regulated inflammatory mode of cell death , 2018, Journal of Neuroinflammation.

[15]  Nicholas G Zaorsky,et al.  Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. , 2018, International journal of radiation oncology, biology, physics.

[16]  M. Tsuboi,et al.  Long‐term survival outcome after postoperative recurrence of non‐small‐cell lung cancer: who is ‘cured’ from postoperative recurrence? , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[17]  Pei Zhang,et al.  Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer , 2017, Technology in cancer research & treatment.

[18]  Mi-bo Tang,et al.  Necroptosis in neurodegenerative diseases: a potential therapeutic target , 2017, Cell Death and Disease.

[19]  G. Brumatti,et al.  Relevance of necroptosis in cancer , 2017, Immunology and cell biology.

[20]  L. Zitvogel,et al.  Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy , 2016, Oncoimmunology.

[21]  Sarah I. Alothman,et al.  The Necrosome Promotes Pancreas Oncogenesis via CXCL1 and Mincle Induced Immune Suppression , 2016, Nature.

[22]  A. Thorburn,et al.  Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics , 2015, Cell Research.

[23]  P. Vandenabeele,et al.  Necroptosis and its role in inflammation , 2015, Nature.

[24]  Ling-gang Wu,et al.  Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis , 2013, Nature Cell Biology.

[25]  W. Curran,et al.  Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma , 2013, Cancer.

[26]  L. Lang-Lazdunski.  Surgery for nonsmall cell lung cancer , 2013, European Respiratory Review.

[27]  Peter Vandenabeele,et al.  Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. , 2013, Immunity.

[28]  Kenta Moriwaki,et al.  The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis , 2012, Cell.

[29]  Xiaodong Wang,et al.  Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase , 2012, Cell.

[30]  Guanghua Xiao,et al.  The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. , 2009, Cancer research.

[31]  Eden R Martin,et al.  No gene is an island: the flip-flop phenomenon. , 2007, American journal of human genetics.

[32]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[33]  Frank C. Detterbeck,et al.  The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.

[34]  X. Wang,et al.  Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. , 2015, Neoplasma.

[35]  Ling He,et al.  Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. , 2013, OncoTargets and therapy.